PTJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


PHYS THER
Vol. 74, No. 3, March 1994, pp. 253-263

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Personius, K.
Right arrow Articles by McDermott, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Personius, K.
Right arrow Articles by McDermott, M.

Article

Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group

KE Personius, S Pandya, WM King, R Tawil, and MP McDermott

BACKGROUND AND PURPOSE. The natural history of facioscapulohumeral muscular dystrophy (FSHD) has not been studied prospectively. Knowledge of the natural progression of any disease provides essential information for the design of clinical trials. We present a protocol for the study of the natural history of FSHD using quantitative muscle testing (QMT), manual muscle testing (MMT), and functional testing. SUBJECTS. Thirty-two persons with FSHD (mean age = 36.1 years, SD = 9.6, range = 17-49) and 32 age- and gender-matched volunteer controls (mean age = 35.8 years, SD = 8.0, range = 23-50) served as subjects. METHODS. Using standardized testing procedures, we examined intrarater reliability of the MMT, QMT, and functional testing measurements in both groups. We also examined interrater reliability in 7 subjects with FSHD. Eighteen muscle groups were tested for each subject using QMT and MMT. RESULTS. Intraclass correlation coefficient (ICC) values ranged from .86 to .99 for intrarater reliability and from .86 to .99 for interrater reliability of QMT measurements. Weighted kappa values of .81 to .98 for intrarater reliability and .50 to 1.00 for interrater reliability were obtained for MMT measurements. Intrarater ICCs for various functional testing measures ranged from .60 to .97. In addition, the comparability of the two QMT machines used in the study was demonstrated by testing the same set of volunteer controls on each machine's linear force transducer (ICC = .89-.98). CONCLUSION AND DISCUSSION. We conclude that this standardized testing protocol produces reliable measurements of muscle strength and functional ability in subjects with FSHD.


This article has been cited by other articles:


Home page
NeurologyHome page
M. R. Rose, M. K. Sharief, J. Priddin, V. Nikolaou, L. Hull, C. Unwin, R. Ajmal-Ali, R. A. Sherwood, A. Spellman, A. David, et al.
Evaluation of neuromuscular symptoms in UK Gulf War veterans: A controlled study
Neurology, November 9, 2004; 63(9): 1681 - 1687.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
E.L. van der Kooi, O.J.M. Vogels, R.J.G.P. van Asseldonk, E. Lindeman, J.C.M. Hendriks, M. Wohlgemuth, S.M. van der Maarel, and G.W. Padberg
Strength training and albuterol in facioscapulohumeral muscular dystrophy
Neurology, August 24, 2004; 63(4): 702 - 708.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
The Muscle Study Group
Randomized pilot trial of high-dose {beta}INF-1a in patients with inclusion body myositis
Neurology, August 24, 2004; 63(4): 718 - 720.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
Randomized pilot trial of {beta}INF1a (Avonex) in patients with inclusion body myositis
Neurology, November 13, 2001; 57(9): 1566 - 1570.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. T. Kissel, M. P. McDermott, J. R. Mendell, W. M. King, S. Pandya, R. C. Griggs, and R. Tawil
Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy
Neurology, October 23, 2001; 57(8): 1434 - 1440.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M. Stangel, F. Boegner, C. H Klatt, C. Hofmeister, and S. Seyfert
Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis
J. Neurol. Neurosurg. Psychiatry, January 1, 2000; 68(1): 89 - 92.
[Abstract] [Full Text]


Home page
NeurologyHome page
S. R. Schwid, C. A. Thornton, S. Pandya, K. L. Manzur, M. Sanjak, M. D. Petrie, M. P. McDermott, and A. D. Goodman
Quantitative assessment of motor fatigue and strength in MS
Neurology, September 1, 1999; 53(4): 743 - 743.
[Abstract] [Full Text] [PDF]


Home page
Neurorehabil Neural RepairHome page
C. T. Bever JR, P. A. Anderson, G. V. Smith, H. S. Panitch, and K. P. Johnson
Isometric Measurement of Hamstrings and Quadriceps Strength in Multiple Sclerosis Patients: Sensitivity and Variability
Neurorehabil Neural Repair, January 1, 1995; 9(4): 221 - 227.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Physical Therapy Association.